SpikoGen booster shows promise in small COVID-19 study
NCT ID NCT05542862
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested the SpikoGen vaccine as a booster shot in 81 adults who had already received a full course of any COVID-19 vaccine. The goal was to see if a third or fourth dose of SpikoGen could raise antibody levels and provide protection. Researchers measured immune responses and tracked safety, including any side effects or infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SpikoGen vaccine (recombinant spike protein based COVID-19 vaccine)
- What this could lead to
- If successful, this could show that SpikoGen is a safe and effective booster option for people who received different types of COVID-19 vaccines.
- What could go wrong
- This is a small, completed Phase 3 trial with only 81 participants, so results may not apply to larger populations. The study focuses on antibody levels, not long-term protection against infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ARASMI
Adelaide, South Australia, 5042, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?